Physician profile
Paul J Lee
NPI 1568536043
$1,045.29
in general payments reported to CMS, 2019-2025
11 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2021: $75.73 · 2022: $20.73 · 2023: $107 · 2024: $459 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $226.48 | 2023-2025 | Eylea Hd |
| Sandoz INC. | $221.54 | 2024-2025 | Cimerli |
| Genentech USA, INC. | $126.60 | 2019-2025 | Vabysmo |
| Eyepoint US, INC. | $96.46 | 2021-2022 | |
| Sight Sciences, INC. | $89.59 | 2019 | |
| Coherus Oncology, INC. | $66.06 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $63.70 | 2025 | Syfovre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.86 | 2019 | |
| Alcon Vision LLC | $44.09 | 2024 | Centurion |
| Abbvie INC. | $31.11 | 2024 | |
| Astellas Pharma US INC | $30.80 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.